Skip to main content

Jeffrey W Cooney

Assistant Professor of Neurology
Neurology, Movement Disorders

Overview


I see patients with a broad range of movement disorders, including Parkinson's disease, tremors, ataxia, dystonia, tics, and Huntington's disease. I employ deep brain stimulation (DBS) therapy for selected patients with Parkinson's disease, tremor, or dystonia, and use botulinum toxin injections for certain patients with dystonia, tremors, or tics. I work with an interdisciplinary team of physicians, therapists, and other healthcare providers, with the overall goal of helping to improve the lives of patients with complex neurological diseases.

Current Appointments & Affiliations


Assistant Professor of Neurology · 2021 - Present Neurology, Movement Disorders, Neurology

In the News


Published May 11, 2018
Faculty Spotlight: Jeffrey W. Cooney, MD

View All News

Recent Publications


Initial Clinical Outcome With Bilateral, Dual-Target Deep Brain Stimulation Trial in Parkinson Disease Using Summit RC + S.

Journal Article Neurosurgery · July 1, 2022 BACKGROUND: Deep brain stimulation (DBS) is an effective therapy in advanced Parkinson disease (PD). Although both subthalamic nucleus (STN) and globus pallidus (GP) DBS show equivalent efficacy in PD, combined stimulation may demonstrate synergism. OBJECT ... Full text Open Access Link to item Cite

Telemedicine and Deep brain stimulation - Current practices and recommendations.

Journal Article Parkinsonism Relat Disord · August 2021 The use of telemedicine in the management of chronic neurological conditions including movement disorders has expanded over time. In addition to enabling remote access to specialized care, telemedicine has also been shown to reduce caregiver burden and to ... Full text Link to item Cite
View All Publications

Recent Grants


An Integrated Biomarker Approach to Personalized, Adaptive Deep Brain Stimulation in Parkinson Disease

ResearchInvestigator · Awarded by National Institute of Neurological Disorders and Stroke · 2023 - 2027

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy

Clinical TrialPrincipal Investigator · Awarded by Teva Branded Pharmaceutical Products R&D, Inc · 2024 - 2026

View All Grants

Education, Training & Certifications


University of North Carolina, Chapel Hill · 2010 M.D.